CIRCLE8 GROUP INC 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File No. 333-150332 SEQLL INC. (Exact name of registrant as specified in its charter) Delaware 46-5319744 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 3 Federal Street Billerica , MA 01821 (Address of principal executive office) (Zip Code) (781) 460-6016 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.0001 per share SQL The Nasdaq Stock Market LLC Warrants to purchase Common Stock SQLLW The Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of May 12, 2022, there were 11,886,379 shares of registrant’s common stock outstanding. TABLE OF CONTENTS PAGE PART I FINANCIAL INFORMATION 1 Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 1 Condensed Consolidated Statements of Operations for the three months ended March 31, 2022 and 2021. 2 Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three months ended March 31, 2022 and 2021. 3 Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021. 4 Notes to the Interim Unaudited Condensed Consolidated Financial Statements 5 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 15 Item 3. Quantitative and Qualitative Disclosures about Market Risk 21 Item 4. Controls and Procedures 21 PART II OTHER INFORMATION 22 Item 1. Legal Proceedings 22 Item 1A. Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 22 Item 3. Default Upon Senior Securities 22 Item 4. Mine Safety Disclosures 23 Item 5. Other Information 23 Item 6. Exhibits 23 Signatures 24 i EXPLANATORY NOTE In this Quarterly Report on Form 10-Q, and unless the context otherwise requires, the “Company,” “we,” “us,” and “our” refer to SeqLL Inc. and its wholly owned subsidiary SeqLL, LLC, taken as a whole. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains “forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in this report and in other documents which we file with the Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to: ● the success, cost and timing of our product development activities, including statements regarding the timing of initiation and completion of our research and development programs; ● developments regarding next generation sequencing technologies; ● our expectations regarding the market size and growth potential for our business; ● our ability to generate sustained revenue or achieve profitability; ● the potential for our identified research priorities to advance our technology; ● the pricing and expected gross margin for our products; ● the other factors discussed in the “Risk Factors” section and elsewhere in this report. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the filing date of this report. ii PART I. FINANCIAL INFORMATION Item 1: Financial Statements SeqLL Inc. Condensed Consolidated Balance Sheets March 31, 2022 December 31, 2021 Assets (Unaudited) Current assets Cash and cash equivalents $ 8,859,317 $ 4,015,128 Marketable securities - 5,933,364 Accounts receivable, net 29,514 30,714 Other receivables 125,672 34,965 Inventory 228,533 224,155 Prepaid expenses 123,118 186,056 Total current assets 9,366,154 10,424,382 Other assets Property and equipment, net 255,490 265,267 Operating lease right-of-use asset 1,455,194 - Other assets 111,250 50,488 Total assets $ 11,188,088 $ 10,740,137 Liabilities and Stockholders’ Equity Current liabilities Accounts payable $ 624,449 $ 871,364 Accrued expenses 327,418 311,405 Non-convertible promissory notes - current 1,375,000 1,375,000 Current portion of operating lease liability 27,068 - Total current liabilities 2,353,935 2,557,769 Non-current liabilities Operating lease liability, less current portion 1,533,825 - Total liabilities 3,887,760 2,557,769 Commitments and contingencies (Note 11) Stockholders’ equity Preferred stock, $ 0.00001 par value; 20,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021 - - Common stock, $ 0.00001 par value; 80,000,000 shares authorized; 11,886,379 shares issued and outstanding as of March 31, 2022 and December 31, 2021 119 119 Additional paid-in capital 22,652,014 22,596,100 Accumulated deficit ( 15,351,805 ) ( 14,413,851 ) Total stockholders’ equity 7,300,328 8,182,368 Total liabilities and stockholders’ equity $ 11,188,088 $ 10,740,137 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 SeqLL Inc. Condensed Consolidated Statements of Operations (Unaudited) Three months ended March 31, 2022 2021 Revenue Sales $ - $ 26,100 Grant revenue 47,482 34,633 Total revenue 47,482 60,733 Cost of sales - 27,951 Gross profit 47,482 32,782 Operating expenses Research and development 334,670 17,955 General and administrative 584,872 387,387 Total operating expenses 919,542 405,342 Operating loss ( 872,060 ) ( 372,560 ) Other (income) and expenses Unrealized gain on marketable securities ( 54,508 ) - Realized loss on marketable securities 106,324 - Other income ( 2,728 ) - Loss on extinguishment of convertible notes - 934,257 Interest expense 16,806 107,801 Net loss $ ( 937,954 ) $ ( 1,414,618 ) Net loss per share - basic and diluted $ ( 0.08 ) $ ( 0.29 ) Weighted average common shares - basic and diluted 11,886,379 4,864,862 The accompanying notes are an integral part of these condensed consolidated financial statements. 2 SeqLL Inc. Condensed Consolidated Statements of Changes in Stockholders’ Equity (Deficit) For the Three Months Ended March 31, 2021 and 2022 (Unaudited) Preferred Stock Common Stock Additional Paid-In Accumulated Total Stockholders’ Shares Amount Shares Amount Capital Deficit Equity Balance as of December 31, 2021 - $ - 11,886,379 $ 119 $ 22,596,100 $ ( 14,413,851 ) $ 8,182,368 Stock-based compensation expense - - - - 55,914 - 55,914 Net loss - - - - - ( 937,954 ) ( 937,954 ) Balance as of March 31, 2022 - $ - 11,886,379 $ 119 $ 22,652,014 $ ( 15,351,805 ) $ 7,300,328 Preferred Stock Common Stock Additional Paid-In Accumulated Total Stockholders’ Equity Shares Amount Shares Amount Capital Deficit (Deficit) Balance as of December 31, 2020 5,791,665 $ 58 4,864,862 $ 49 $ 6,856,020 $ ( 10,710,293 ) $ ( 3,854,166 ) Stock-based compensation expense - - - - 1,007 - 1,007 Net loss - - - - - ( 1,414,618 ) ( 1,414,618 ) Balance as of March 31, 2021 5,791,665 $ 58 4,864,862 $ 49 $ 6,857,027 $ ( 12,124,911 ) $ ( 5,267,777 ) The accompanying notes are an integral part of these condensed consolidated financial statements. 3 SeqLL Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) Three months ended March 31, 2022 2021 Cash Flows from Operating Activities Net loss $ ( 937,954 ) $ ( 1,414,618 ) Adjustment to reconcile net loss to net cash used in operating activities: Depreciation 16,712 21,456 Unrealized gain on marketable securities ( 54,508 ) - Realized loss on marketable securities 106,324 Loss on extinguishment of notes - 934,257 Stock-based compensation 55,914 1,007 Non-cash lease expense 27,509 - Changes in operating assets and liabilities: Accounts receivable, net 1,200 ( 15,320 ) Other receivables ( 12,517 ) 74,182 Prepaid expenses 62,938 - Inventory ( 4,378 ) 4,507 Other assets ( 60,762 ) - Accounts payable ( 246,915 ) 74,685 Accrued expenses 16,013 84,193 Net cash used in operating activities ( 1,030,424 ) ( 235,651 ) Cash Flows from Investing Activities Purchases of lab equipment ( 6,935 ) ( 5,250 ) Purchases of marketable securities ( 590 ) - Sales of marketable securities 5,882,138 - Net cash provided by (used in) investing activities 5,874,613 ( 5,250 ) Cash Flows from Financing Activities Proceeds from issuance of convertible notes - 250,000 Net increase in cash and cash equivalents 4,844,189 9,099 Cash and cash equivalents, beginning of period 4,015,128 - Cash and cash equivalents, end of period $ 8,859,317 $ 9,099 Supplemental Disclosures of Cash Flow Information and Non-Cash Transactions: Right-of-use asset acquired through operating lease upon adoption of ASC 842 $ 1,481,646 - The accompanying notes are an integral part of these consolidated financial statements. 4 SeqLL Inc. Notes to Condensed Consolidated Financial Statements For the Three Months Ended March 31, 2022 and 2021 (Unaudited) Note 1 – Nature of Operations and Basis of Presentation SeqLL Inc. was incorporated as a Delaware corporation on April 3, 2014. On April 8, 2014, SeqLL Inc. acquired a 100 % ownership interest in SeqLL, LLC (“Subsidiary”), a domestic limited liability company formed on March 11, 2013 in the State of Massachusetts. SeqLL Inc. is a holding company of the Subsidiary (together the “Company” or SeqLL”) and is a life sciences company focused on the development and application of innovative genetic analysis technologies and the monetization of that technology and related intellectual property. The Subsidiary owns technology to enable the analysis of large volumes of genetic material by directly sequencing single molecules of DNA or RNA. The Subsidiary’s principal office is located in Billerica, Massachusetts. Initial Public Offering On August 31, 2021, the Company completed its initial public offering (“IPO”) whereby it sold 3,060,000 units, each unit consisting of one share of the Company’s common stock and a warrant to purchase one share of common stock at an exercise price of $ 4.25 per share (the “Warrants”), at a price to the public of $ 4.25 per unit. The gross proceeds from the IPO were approximately $ 13.0 million and were offset by $ 3.2 million in offering costs, of which $ 1.6 million was paid in cash and $ 1.6 million was issued in warrants issued to Maxim Group LLC (“Underwriter”) (see Note 8). In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock automatically converted into 3,130,622 shares of common stock (see Note 9). Additionally, the outstanding convertible notes converted into 641,895 shares of common stock (see Note 7). Risks and Uncertainties The Company is subject to a number of risks similar to other companies in its industries, including rapid technological change, competition from larger pharmaceutical and biotechnology companies and dependence on key personnel. The extent of the impact of the COVID-19 pandemic on the Company’s business continues to be highly uncertain and difficult to predict, as the responses that the Company, other businesses and governments are taking continue to evolve. Furthermore, capital markets and economies worldwide have also been negatively impacted by the COVID-19 pandemic, and it is possible that it could cause a lasting national and/or global economic recession. Policymakers around the globe have responded with fiscal policy actions to support the healthcare industry and economy as a whole. The magnitude and overall effectiveness of these actions remain uncertain. The severity of the impact of the COVID-19 pandemic on the Company’s business depends on a number of factors, including, but not limited to, the duration and severity of the pandemic and the extent and severity of the impact on the Company’s service providers, suppliers, contract research organizations and the Company’s funding sources, all of which are uncertain and cannot be predicted. The COVID-19 pandemic has adversely affected the Company’s sales and results of operations from the beginning of the pandemic through March 31, 2022 and may continue to adversely affect its business. The extent to which the COVID-19 pandemic may in the future materially impact the Company’s financial condition, liquidity or results of operations is uncertain. Basis of Presentation The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, SeqLL, LLC. All intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements of the Company have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated financial position as of March 31, 2022 and its results of operations for the three-month periods ended March 31, 2022 and 2021, and changes in shareholders’ equity and cash flows for the periods presented. The results disclosed in the condensed consolidated statements of operation for the three-months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2021 filed with the Securities and Exchange Commission. 5 Note 2 – Significant Accounting Policies During the three-month period ended March 31, 2022, there were no changes to the significant accounting policies in relation to what was described in the Annual Report on Form 10-K for the year ended December 31, 2021, other than the items noted in the Recently Adopted Accounting Standards section below. Use of Estimates The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”), requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include but are not limited to stock-based compensation expense and research and development accruals. Actual results could differ from those estimates and changes in estimates may occur. Inventory Inventory consists of finished goods, work-in-process and raw materials and is valued at the lower of cost or net realizable value, determined by the first-in, first-out (“FIFO”) method. As the Company manufactures the finished goods and work-in-process materials, overhead costs are included in inventory. The Company evaluates the carrying cost of finished goods, work-in-process and raw materials items. To the extent that such costs exceed future demand estimates and /or exhibit historical turnover at rates less than current inventory levels, the Company reduces the carrying value of the applicable inventories. Inventory consisted of the following: March 31, December 31, 2022 2021 Raw materials $ 97,546 $ 91,995 Work in process 130,987 132,160 Total inventory $ 228,533 $ 224,155 Stock-based Compensation The Company’s share-based compensation program grant awards include stock options and restricted stock awards. The fair value of stock option grants is estimated as of the date of the grant using the Black-Scholes option pricing model. The fair value of restricted stock awards is based on the fair value of the Company’s common stock on the date of the grant. The fair value of the stock-based awards are then expensed over the requisite service period, generally the vesting period, for each award. The Company’s expected stock price volatility assumption is based on the volatility of comparable public companies. The expected term of a stock option granted to employees and directors (including non-employee directors) is based on the average of the contractual term (generally 10 years) and the vesting period. For non-employee options, the expected term is the contractual term. The risk-free interest rate is based on the yield of U.S. Treasury securities consistent with the life of the option. No dividend yield was assumed as the Company does not pay dividends on its common stock. The Company recognizes forfeitures related to stock-based awards as they occur. The Company has periodically granted stock options and restricted stock awards to consultants for services pursuant to the Company’s stock plans at the fair market value on the respective dates of grant. Should the Company terminate any of its consulting agreements, the unvested options underlying the agreements would be cancelled. For awards granted to consultants and non-employees, compensation expense is recognized over the vesting period of the awards, which is generally the period services are rendered by such consultants and non-employees. 6 The assumptions used in determining the fair value of share-based awards granted in three-month period ended March 31, 2022 are as follows: March 31, 2022 Risk-free interest rate 1.64 % Expected option life 6 – 6.1 years Expected dividend yield 0 % Expected stock price volatility 54 % Segments The Company operates in a single business segment that includes the design, development and manufacturing of genetic analysis technologies. Leases In the first quarter of 2022, the Company adopted ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”). The Company assesses its contracts at inception to determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly or implicitly identified asset for a period of time. The Company has recognized right-of-use assets and lease liabilities that represent the net present value of future operating lease payments utilizing a discount rate corresponding to the Company’s incremental borrowing rate and amortizing over the remaining terms of the leases. The Company accounts for the leases of less than 12 months as short-term leases. See the Recently Adopted Accounting Standards below for additional information related to the adoption of this accounting standard. Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potentially dilutive securities if their effect is antidilutive. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury stock and if-converted methods. Dilutive common stock equivalents are comprised of convertible preferred stock, convertible promissory notes, options outstanding under the Company’s stock option plan and warrants. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. The following potential shares of common stock were not considered in the computation of diluted net loss per share as their effect would have been antidilutive: March 31, 2022 2021 Convertible preferred stock - 5,791,665 Convertible promissory notes - 641,895 Stock options 2,003,919 818,915 Warrants for common stock 4,393,396 711,946 7 Recently Adopted Accounting Standards In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt— Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for the public companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard on January 1, 2022, which had no material impact to the Company’s condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02 which establishes new accounting and disclosure requirements for leases. ASU No. 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. The Company adopted ASU 2016-02 in the first quarter of 2022 using the effective date approach to recognize and measure leases as of the adoption date. The Company has elected to utilize the available practical expedient to not separate lease components from non-lease components as well as the package of practical expedients that allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. At the date of adoption on January 1, 2022, this guidance had no impact to the Company’s condensed consolidated financial statements. Recently Issued Accounting Standards The Company does not believe that any recently issued but not yet effective accounting pronouncements will have a material effect on the accompanying condensed consolidated financial statements. Note 3 – Accrued Expenses Accrued expenses consisted of the following: March 31, December 31, 2022 2021 Accrued interest 232,879 216,073 Other 94,539 95,332 $ 327,418 $ 311,405 Note 4 – Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and requires disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable inputs such as quoted prices in active markets. Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. 8 As of March 31, 2022, the Company had $ 5,942,158 of investments in money-market funds, included above within cash and cash equivalents. The fair value of these investments was determined with Level 1 inputs through references to quoted market prices. The change in the fair value of the Amended Notes (Note 7), deemed the Level 3 liabilities, was immaterial for the three months ended March 31, 2021. There were no assets or liabilities measured at fair value on a non-recurring basis during the three months ended March 31, 2021 or 2020. Note 5 – Stock Option Plan The Company’s 2014 Equity Incentive Plan (the “2014 Plan”) permits the grant of options for its common stock and shares of common stock to its employees, board members and consultants for up to 3,500,000 shares. As of March 31, 2022, there were 1,496,081 shares available for future issuance under the 2014 Plan. Generally, option awards are granted with an exercise price equal to the fair value of the Company’s stock at the date of grant and vest over a period of three to four years . No option may have a term in excess of ten years from the option grant date. Certain option and share awards provide for accelerated vesting if there is a change in control (as defined by the 2014 Plan). The weighted average grant date fair value of options granted in the three-month period ended March 31, 2022 was $ 0.89 per share. No option awards were granted during the three months ended March 31, 2021. The stock option activity for the period ended March 31, 2022 is as follows: Number of Options Weighted- Average Exercise Price per Share Weighted Average Remaining Contractual Term (in Years) Outstanding as of December 31, 2021 918,919 $ 2.09 5.79 Granted 1,085,000 $ 1.71 Outstanding of March 31, 2022 2,003,919 $ 1.88 7.84 Exercisable at March 31, 2022 918,626 $ 2.09 5.54 During the three-month periods ended March 31, 2022 and 2021, the Company recorded $ 55,914 and $ 1,007 , respectively, of stock-based compensation associated with vesting of stock options, of which $ 38,746 and $ 1,007 were included in general and administrative expenses for the three-month periods ended March 31, 2022 and 2021, respectively, and $ 17,168 and $ 0 were included in research and development expenses for the three-month periods ended March 31, 2022 and 2021, respectively. As of March 31, 2022, there was approximately $ 911,799 of unrecognized compensation expense related to unvested share-based compensation awards, which will be recognized over a weighted average period of approximately 1.87 years . 9 Note 6 – Related Party Transactions At March 31, 2022 and December 31, 2021, the Company had the following outstanding payables, which are included within the Company’s accounts payable above, to affiliates of its shareholders for past services: March 31, 2022 December 31, 2021 Genomic Diagnostic Technologies $ 23,725 $ 23,725 St. Laurent Institute 299,552 313,679 St. Laurent Realty, Inc. 7,558 27,913 Total related party payables $ 330,835 $ 365,317 The above entities are affiliated with (1) William C. St. Laurent, a former member of the Company’s board of directors, (2) relatives of Mr. St. Laurent or (3) entities controlled by the St. Laurent family, who are controlling shareholders of the Company. St. Laurent Realty, Inc. and Genomic Diagnostic Technologies assisted the Company by previously providing corporate accounting support; St. Laurent Institute, a not-for-profit company, provided bioinformatics specialist support for certain sequencing services. Note 7 – Notes Payable The Company entered into a series of convertible promissory notes (the “Convertible Notes”) through April 8, 2019, with certain preferred stockholders amounting to $ 905,000 . The Convertible Notes had a one-year term and accrued interest at 10 % per annum. The Convertible Notes were convertible at the lower of $ 3.10 per share or a 20 % discount to the share price paid by the purchasers of equity securities in the Company’s next Qualified Financing, as defined in the convertible note agreements. From April 29, 2019 to April 29, 2020, the Company entered into a series of non-convertible promissory notes (the “Promissory Notes”) with a certain preferred stockholder amounting to $ 1,375,000 . The Promissory Notes had a one-year term with interest accruing at 10 % per annum. In November and December 2020, the Company issued senior secured convertible promissory notes to a third-party investor amounting to $ 200,000 . These notes accrued interest at 10 % per annum, were to be repaid at the earlier of December 31, 2022 , or the Company’s next qualified financing of a minimum of $ 7.5 million (as defined in the notes agreement), and were convertible into the Company’s common stock at $ 3.75 per share. On December 31, 2020, the Company issued a non-convertible promissory note to St. Laurent Investments LLC amounting to $ 426,020 due July 31, 2022 , bearing 10 % interest per annum in exchange for the accrued interest on all their notes outstanding through that date. From January to March 2021, the Company issued senior secured convertible promissory notes to investors for total proceeds of $ 250,000 . The Convertible Notes accrued interest at 10 % per annum, matured at the earlier of December 31, 2022 , or the Company’s next qualified equity offering of a minimum of $ 7.5 million, and were convertible at $ 3.75 per share. On February 3, 2021, the preferred stockholder and the holder of $ 2,910,710 in the Convertible Notes and Promissory Notes granted the Company an extension on all their notes to be repaid on or before July 31, 2022. This amendment was accounted for on a prospective basis under the troubled debt restructuring guidance. In March 2021, the Company entered into a series of agreements with the noteholders to automatically convert $ 786,730 in outstanding Promissory Notes and $ 1,305,000 in Convertible Notes (together, “Amended Notes”), to common stock upon the closing of the IPO (“Conversion Agreements”), of which $ 1,552,683 was held by St. Laurent Investments, LLC and its affiliates. Under the terms of the Conversion Agreements, $ 826,020 and $ 1,265,710 in Amended Notes were to be converted at the closing of the IPO based on the $ 3.75 and $ 3.10 conversion prices, respectively. Since the automatic conversion could result in a material benefit to the noteholders, this amendment was deemed substantive and was accounted for as an extinguishment of debt. Accordingly, the Company recognized a loss on extinguishment of debt totaling $ 934,257 in the consolidated statement of operations for the three months ended March 2021, which represented the excess of the fair value of the Amended Notes totaling $ 3,118,235 over their carrying value of $ 2,183,978 . The Company elected the option to account for the Amended Notes at fair value, with the changes in fair value recognized in the statement of operations. The fair value of the Amended Notes was estimated using probability weighted expected payouts under various settlement scenarios, discounted to their present value based on the estimated effective rate of return. 10 On April 29, 2021, the Company entered into an agreement with a noteholder to automatically convert an additional $ 50,000 in outstanding Amended Notes, including any accrued interest, to common stock upon the closing of the IPO at the conversion price of $ 3.75 per share. At the IPO date, the Amended Notes automatically converted based on their original terms into 641,895 shares of common stock. The fair value of the Amended Notes of $ 3,364,198 immediately prior to the conversion, less $ 141,884 cash payment related to the accrued interest, was reclassified into the additional paid in capital on the condensed consolidated balance sheet. The fair value of the Amended Notes at the conversion date was estimated based on the fair value of the common stock issued upon the conversion. The Company recognized $ 195,962 loss due to the change in fair value of the Amended Notes between the amendment date and their conversion at the IPO date. In October 2021, the Company entered into an agreement with St. Laurent Investments LLC to reduce the interest on $ 1,375,000 aggregate principal amount of the Promissory Note from 10 % to 5 % per year starting on October 1, 2021. The Company accounted for this transaction as a modification on a prospective basis. In October 2021, the Company repaid $ 270,000 of the Promissory Notes to William C. St Laurent in cash. In connection with all the Convertible Notes and Promissory Notes issued during 2021 and 2020, the Company issued warrants to noteholders to purchase the total of 66,665 and 53,333 shares of the Company’s common stock, including 11,466 to the placement agent (see Note 8). The grant-date fair values of these warrants were immaterial. For the three-month periods ended March 31, 2022 and 2021, interest expense was $ 16,806 and $ 107,801 , respectively. Note 8 – Common Stock Warrants On March 16, 2021, the Company made a down payment to ShareIntel-Shareholder Intelligence Services, LLC for anticipated services connected to the Company’s planned public offering, which was in the form of issuing 9,865 warrants to purchase common stock at $ 4.10 per share, with an expiration date of June 30, 2024. The warrants are exercisable starting at their issuance dates. On August 31, 2021, the Company sold an aggregate of 3,060,000 units at a price to the public of $ 4.25 per unit, each unit consisting of one share of the Company’s common stock and a warrant to purchase one share of common stock at an exercise price of $ 4.25 per share. In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriter a 45-day option to purchase up to 459,000 additional shares of common stock, and/or 459,000 additional warrants, to cover over-allotments in connection with the Offering. The Underwriter partially exercised this option and purchased 459,000 warrants on the closing date at $0.01 per Warrant, for the total proceeds of $4,590. These warrants are exercisable at any time from the issuance date at $ 4.25 for common stock shares and have a five-year term. The warrants may be exercised for cash or, under certain limited circumstances, through cashless exercise. The Company may redeem the outstanding warrants, in whole and not in part, at $0.001 per warrant if, after thirteen months from the issuance date, (i) the daily volume weighted average price of the Common Stock for each of 10 consecutive trading days (Measurement Period) exceeds $12.75 (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like after the issuance date), (ii) the average daily volume for such Measurement Period exceeds $1,000,000 per Trading Day and (iii) the holders of warrants are not in possession of any information that constitutes, or might constitute, material non-public information which was provided by the Company, any of its subsidiaries, or any of their officers, directors, employees, agents or affiliates. 11 Pursuant to the Underwriting Agreement, on August 31, 2021 and September 29, 2021, the Company also issued to the Underwriter warrants to purchase up to a total of 162,450 shares of common stock as a compensation for their services. These warrants are exercisable at any time from the issuance date at $ 4.675 per share of common stock and have a term of five years through August 26, 2026. The total fair value of the warrants granted to the Underwriter was $ 1,642,486 at the issuance date. The Company estimated the fair value of the warrants using the Black-Scholes option pricing model based on the following assumptions: Risk-free interest rate 0.77 % - 1.01 % Expected life 5 years Dividend yield 0 % Volatility 67 % The following table summarizes information with regard to outstanding warrants to purchase common stock as of March 31, 2022, which are exercisable starting at their issuance dates. All warrants are accounted for as equity based on the US GAAP guidance applicable to the instruments indexed to an entity’s own stock. Issuance Date Number of Shares Issuable Upon Exercise of Outstanding Warrants Exercise Price Expiration Date 5/4/2017 3,860 $ 3.10 5/3/2022 6/14/2017 1,351 $ 3.10 6/13/2022 8/30/2018 3,088 $ 3.10 8/29/2023 9/30/2018 60,506 $ 3.10 9/29/2023 9/30/2018 486,486 $ 2.16 9/29/2023 10/17/2018 1,157 $ 3.10 10/16/2023 11/2/2018 964 $ 3.10 11/1/2023 11/9/2018 964 $ 3.10 11/8/2023 11/16/2018 964 $ 3.10 11/15/2023 11/29/2018 964 $ 3.10 11/28/2023 12/21/2018 964 $ 3.10 12/20/2023 12/27/2018 964 $ 3.10 12/26/2023 1/31/2019 1,930 $ 3.10 1/30/2024 2/7/2019 1,640 $ 3.10 2/6/2024 2/21/2019 1,640 $ 3.10 2/20/2024 3/20/2019 3,378 $ 3.10 3/18/2024 4/8/2019 1,930 $ 3.10 4/6/2024 11/19/2020 53,333 $ 4.10 6/30/2024 11/19/2020 8,533 $ 4.10 6/30/2024 1/8/2021 13,333 $ 4.10 6/30/2024 1/11/2021 26,666 $ 4.10 6/30/2024 2/13/2021 13,333 $ 4.10 6/30/2024 3/16/2021 10,665 $ 4.10 6/30/2024 3/16/2021 13,333 $ 4.10 6/30/2024 8/31/2021 3,519,000 $ 4.25 8/31/2026 8/31/2021 153,000 $ 4.675 8/26/2026 9/29/2021 9,450 $ 4.675 8/26/2026 4,393,396 12 Note 9 – Preferred Stock The Company had outstanding preferred stock as of December 31, 2020: Shares issued Issuance price per share Series A-1 Convertible Preferred Stock 3,125,000 $ 0.32 Series A-2 Convertible Preferred Stock 2,666,665 $ 1.68 Series A Preferred stock 5,791,665 The Series A-1 Preferred Stock (“Series A-1”) and Series A-2 Preferred Stock (“Series A-2” and, collectively with the Series A-1, the “Preferred Stock”), could be converted at any time at the election of the holder into common stock at an initial conversion price determined by dividing the Series A-1 original issue price of $ 0.59 , as amended, by the Series A-1 conversion price of $ 0.59 ; and the Series A-2 original issue price of $ 3.10 , as amended, by the Series A-2 conversion price of $ 3.10 ; both were subject to adjustment for stock splits, stock combinations and the like, and to a weighted-average adjustment for future issuances of common stock, warrants or rights to purchase common stock or securities convertible into common stock for a consideration per share that is less than the then-applicable conversion price, subject to certain exceptions listed in the Charter. The Preferred Stock was subject to automatic conversion upon (i) the closing of an initial public offering of the common stock at a price per share equal to at least $9.25 (as adjusted for any stock splits, stock dividends, combinations, subdivisions, recapitalization or the like) in an underwritten public offering in which the Company raised gross proceeds of at least $10 million or (ii) the consent of holders of at least a majority of the then-outstanding shares of Preferred Stock voting together as a single class. In connection with the IPO, all of the outstanding shares of the Company’s convertible preferred stock automatically converted into 3,130,622 shares of common stock . Note 10 – Marketable Securities In January 2022, the Company sold all of its marketable securities with the original cost $ 5,988,462 . The Company realized $ 106,324 loss on the sale of these securities and recorded the unrealized gain of $ 54,508 on its investments in marketable securities for the three months ended March 31, 2022. Note 11 – Commitments and Contingencies The Company’s office space lease in Woburn, Massachusetts (the “Woburn Lease”) for the Company’s corporate headquarters was on a month-to-month basis since November 2020 and was terminated in February 2022. The rent expense for this lease was $ 14,239 and $ 41,837 for the three-month periods ended March 31, 2022 and 2021, respectively. 13 On February 2, 2022, the Company entered into a lease agreement for approximately 15,638 square feet of its new corporate office space in Billerica, Massachusetts (the “Billerica Lease”). The Billerica Lease has a term of 92 months from its effective date and includes the access to certain additional office space within the same office building through the earlier of August 1, 2022 or the completion of certain tenant improvements (the “Swing Space”). In addition, the Company is required to share in certain taxes and operating expenses of the Billerica Lease. The Billerica lease is classified as an operating lease. At the date of the Billerica lease inception, the Company recorded a right-of-use asset of $ 1,481,646 in operating lease right-of-use asset, as well as a lease liability of $ 12,222 in current liabilities and $ 1,547,614 in long-term liabilities. The operating lease right-of use asset is less than that of the Company’s lease liabilities as of the lease inception date. This is due to the fact that the Company as part of the Billerica lease was allowed certain tenant improvement allowances, of which, amounted to $ 78,190 at lease inception. This lease liability represents the net present value of future lease payments for the lease utilizing a discount rate of 5.98 %, which corresponds to the Company’s incremental borrowing rate. As of March 31, 2022, the remaining lease term was 7.5 years. The Company recorded expense related to the Billerica Lease in the amount of $ 41,526 for the three-months ended March 31, 2022. During the three months ended March 31, 2022, the Company made cash payments of $ 14,018 for amounts included in the measurement of lease liabilities. The following table reconciles the undiscounted lease liabilities to the total lease liabilities recognized on the condensed consolidated balance sheet as of March 31, 2022: 2022 (remaining) $ 74,349 2023 197,307 2024 275,875 2025 284,151 Thereafter 1,142,709 Total undiscounted lease liabilities $ 1,974,391 Less effects of discounting ( 413,498 ) Total lease liabilities $ 1,560,893 Reported as of March 31, 2022: Current portion of operating lease liability $ 27,068 Operating lease liability, less current portion 1,533,825 Total lease liabilities $ 1,560,893 14 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements for the period ended March 31, 2022, and related notes included elsewhere in this filing. This discussion and analysis and other parts of this filing contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under “Risk Factors” and elsewhere in this filing. You should carefully read the “Risk Factors” section of this filing to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section entitled “Cautionary Note Regarding Forward-Looking Statements” in this filing. Overview This overview and outlook provide a high-level discussion of our operating results and significant known trends that affect our business. We believe that an understanding of these trends is important to understanding our financial results for the periods being reported herein as well as our future financial performance. This summary is not intended to be exhaustive, nor is it intended to be a substitute for the detailed discussion and analysis provided elsewhere in this report. About SeqLL We are a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields. We leverage our expertise with True Single Molecule Sequencing (tSMS) technology enabling researchers and clinicians to contribute major advancements to scientific research and development. Our customers are primarily the early adopters of genomics technology and tSMS in academic research, biomarker discovery, and molecular diagnostic product development. Since our incorporation in 2014, we have devoted the majority of our efforts to technology development, business planning, and advancing research collaborations. We incurred net losses of $937,954 and $1,414,618 for the three-month periods ended March 31, 2022 and 2021, respectively. We had negative cash flow from operating activities of $1,030,424 and $235,651 for the three-month periods ended March 31, 2022 and 2021, respectively, and had an accumulated deficit of $15,351,805 as of March 31, 2022. 15 Beginning in 2020, the COVID-19 pandemic and international efforts to control its spread have significantly curtailed the movement of people, goods, services and research worldwide, including in the areas in which we conduct our business and collaborations. We expect the COVID-19 pandemic to continue to impact our business and collaborations in 2022, the size and duration of which is significantly uncertain. Our financial results have been, and will continue to be, impacted by several significant trends, which are described below. While these trends are important to understanding and evaluating our financial results, this discussion should be read in conjunction with our consolidated financial statements and the notes thereto within the Consolidated Financial Statements section in Part I of this report, and trends discussed in “Risk Factors” within Part II of this report. Results of Operations Comparison of the Three-Month Periods Ended March 31, 2022 and 2021 The following table summarizes our results of operations for the three-month periods ended March 31, 2022 and 2021: Three months ended March 31, 2022 2021 Revenue Sales $ - $ 26,100 Grant revenue 47,482 34,633 Total revenue 47,482 60,733 Cost of sales - 27,951 Gross profit 47,482 32,782 Operating expenses Research and development 334,670 17,955 General and administrative 584,872 387,387 Total operating expenses 919,542 405,342 Operating loss (872,060 ) (372,560 ) Other (income) and expenses Unrealized gain on marketable securities (54,508 ) - Realized loss on marketable securities 106,324 - Other income (2,728 ) - Loss on extinguishment of convertible notes - 934,257 Interest expense 16,806 107,801 Net loss $ (937,954 ) $ (1,414,618 ) Revenues Our revenues during the three-month period ended March 31, 2022, were $47,482 as compared to revenues of $60,733 during the three-month period ended March 31, 2021, representing a decrease of $13,251, or 22%. During the three-month period ended March 31, 2022, revenue included grants of $47,482 and no revenues from product sales and research services as compared to revenue in the same period of 2021 from product sales of $15,600, grants of $34,633 and $10,500 in research services. The decrease in revenue was due to the reduction in research services and business activities due to the Company’s relocation to Billerica, Massachusetts. This relocation resulted in the Company temporarily not having facilities that were sufficient to perform its research services and business activities. The Company expects to resume normal operations in the second half of 2022. 16 Gross Profit Gross profit for the three-month period ended March 31, 2022 was $47,482, as compared to gross profit of $32,782 for the three-month periods ended March 31, 2021, which represented a 45% increase primarily due to the fact that the Company had no sales of products or services during the three-month period ended March 31, 2022 due to its relocation to Billerica, Massachusetts. Research and Development Expenses Research and development expenses increased by $316,715, or 1,764%, from $17,955 for the three-month period ended March 31, 2021 compared to $334,670 for the three-month period ended March 31, 2022. The increase in expenses was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic. We expect these expenditures to increase over 2022 and beyond as we increase our research and development efforts to pre-pandemic levels. General and Administrative Expenses General and administrative expenses increased by $197,485, or 51%, from $387,387 for the three-month period ended March 31, 2021 compared to $584,872 for the three-month period ended March 31, 2022. The increase was primarily attributable to increased operating expenses as a public company, including the addition of accounting, legal and audit related expenses, of which approximately $100,000 was related to increased payroll expense and approximately $60,000 was related to the addition of director and officer insurance. General and administrative expenditures will continue to increase during 2022 to support ongoing financial reporting and compliance activities. Interest and Other Income/Loss We recognized interest expense of $16,806 and $107,801 in the three-month periods ended March 31, 2022 and 2021, respectively, representing a decrease of $90,995, or 84%. The decrease in interest expense was due to a decrease in our outstanding indebtedness as a result of the conversion of $2.1 million in notes to equity concurrently with the consumption of our initial public offering on August 31, 2021. We recognized $51,816 in net realized and unrealized losses on the marketable securities during the three-month period ended March 31, 2022. We did not hold such investments during the three-month period ended March 31, 2021. We recognized a loss on extinguishment of debt totaling $934,257 in the three-month period ended March 31, 2021 related to certain convertible notes. The loss on the extinguishment of debt represented the excess of the fair value of these convertible notes totaling $3,075,987 over their carrying value of $2,141,730 at their amendment date in the first quarter of 2021. We did not incur such losses in the three-month period ended March 31, 2022. Net Loss Overall, the net loss decreased by $476,664, or 34%, to $937,954 as compared to $1,414,618 for the period ended March 31, 2021 due to the loss on extinguishment of our convertible notes in the three-month period ended March 31, 2021 in the amount of $934,257, when no such loss occurred during the period ended March 31, 2022. This reduction was offset by an increase in the operating expenses of $514,200 when comparing the three-month period ended March 31, 2022 to the same period in the prior year. Liquidity and Capital Resources The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Even though we experienced negative cash flows from operations of $1,030,424 for the three-month period ended March 31, 2022, as a result of our recent common stock offering in August 2021, we had cash and cash equivalents of $8,859,317 at March 31, 2022. Therefore, we estimate that our available cash resources will be sufficient to fund our operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC. As of March 31, 2022, we had approximately $8.9 million in cash and cash equivalents. Cash and cash equivalents increased $4.8 million at March 31, 2022 as compared to December 31, 2021 due to the sale of approximately $5.9 million in the Company’s marketable securities, offset by the cash spending for operating activities for the three-month period ended March 31, 2022. 17 Since inception, we have funded our operations primarily through equity and debt financings, as well as from modest sales of products and research services. As of March 31, 2022, we had an accumulated deficit of $15,351,805. In August 2021, we issued 3,060,000 shares of common stock to investors in our initial public offering. The gross proceeds from our initial public offering was $13.0 million. We incurred offering expenses of $1.6 million in cash. We also converted $2.1 million of debt into 641,895 shares of common stock at our initial public offering. On September 29, 2021, we issued 189,000 shares of common stock to the underwriters at a price of $4.24 per share from the partial exercise of the overallotment option, increasing the net proceeds by approximately $730,000, net of offering costs. We believe the net proceeds from our initial public offering, together with our cash generated from commercial sales and research activity, will enable us to fund our operations for at least one year from the date this Quarterly Report on Form 10-Q is filed with the SEC. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Our future capital requirements will depend on many factors, including: ● our ability to successfully and further develop our technologies and create innovative products in our markets, including the costs associated with the development of our tSMS platform across multiple market segments, for which we have budgeted approximately $1 million in 2022 and $2 million in 2023 in support of our collaborative efforts in detection tools for heart disease and cancer, and chromatin mapping in genome biology, ● scientific progress in research and development of our collaborative programs, including the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights, as well as the costs associated with any product or technology that we may in-license or acquire; and ● the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; including the need to enter into other collaborations to enhance or complement our product and service offerings. We plan to continue seeking additional financing sources from time to time to meet our working capital requirements, make continued investment in research and development and make capital expenditures needed for us to maintain and expand our business. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, or if we expend capital on projects that are not successful, our ability to continue to support our business growth and to respond to business challenges could be significantly limited. In addition, if we raise additional funds through further issuances of equity or debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. 18 Cash Flows The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented. Three Months Ended March 31, 2022 2021 Cash proceeds provided by (used in): Operating activities $ (1,030,424 ) $ (235,651 ) Investing activities 5,874,613 (5,250 ) Financing activities - 250,000 Net increase (decrease) in cash and cash equivalents $ 4,844,189 $ 9,099 Net cash used in operating activities Net cash used in operating activities was approximately $1 million and $0.24 million for the three-month periods ended March 31, 2022 and 2021, respectively. The increase in operating spending was a result of our progressive return to research and development activities to levels of pre-COVID-19 pandemic. In addition, we experienced the increase in our general and administrative spending since we became a public company in August 2021. We anticipate our research and development efforts and on-going general and administrative costs will generate negative cash flows from operating activities for the foreseeable future. Net cash used in investing activities Net cash provided by (used in) investing activities was approximately $5.9 million and less than $0.1 million for the three-month periods ended March 31, 2022 and 2021, respectively. The increase was primarily attributable to our sales of our entire portfolio of marketable securities during the three-month period ended March 31, 2022. Net cash provided by financing activities Net cash provided by financing activities was $0, and approximately $0.25 million, for the three-month periods ended March 31, 2022 and 2021, respectively. The Company issued $250,000 in convertible notes during the three-month period ended March 31, 2021. There were no equity or debt issuances during the three-month period ended March 31, 2022. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity , which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity’s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, this ASU modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this ASU are effective for the public companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard on January 1, 2022, which had no material impact to the Company’s condensed consolidated financial statements. In February 2016, the FASB issued ASU 2016-02 which establishes new accounting and disclosure requirements for leases. ASU No. 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. The Company adopted ASU 2016-02 in the first quarter of 2022 using the effective date approach to recognize and measure leases as of the adoption date. The Company has elected to utilize the available practical expedient to not separate lease components from non-lease components as well as the package of practical expedients that allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. At the date of adoption on January 1, 2022, this guidance had no impact to the Company’s condensed consolidated financial statements. We do not believe that any other recently issued but not yet effective accounting pronouncements will have a material effect on the accompanying consolidated financial statements. 19 Critical Accounting Policies and Estimates The Company prepares its financial statements and accompanying notes in conformity with accounting principles generally accepted in the United States of America, which require management to make estimates and assumptions about future events that affect reported amounts. Estimations are considered critical accounting estimates based on, among other things, its impact on the portrayal of the Company’s financial condition, results of operations, or liquidity, as well as the degree of difficulty, subjectivity, and complexity in its deployment. Critical accounting estimates address accounting matters that are inherently uncertain due to unknown future resolution of such matters. Management routinely discusses the development, selection, and disclosure of each critical accounting estimates. Other than those noted within Note 2 to our unaudited consolidated financial statements, there have been no significant changes to the Company’s critical accounting policies and estimates during the three-month period ended March 31, 2022 as compared to the information contained in the Company’s 2021 Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. Reference should be made to the consolidated financial statements and related notes included in the 2021 Form 10-K for a full description of other significant accounting policies. JOBS Act Section 107 of the Jumpstart Our Business Startups Act of 2012 (the “JOBS ACT”) provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. For as long as we remain an emerging growth company under the recently-enacted JOBS Act, we will, among other things: ● be permitted to have only two years of audited financial statements and only two years of related selected financial data and management’s discussion and analysis of financial condition and results of operations disclosure; ● be entitled to rely on an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; ● be entitled to reduced disclosure obligations about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and ● be exempt from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements. We currently intend to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to us so long as we qualify as an “emerging growth company.” Among other things, this means that our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an emerging growth company, which may increase the risk that weaknesses or deficiencies in our internal control over financial reporting go undetected. Likewise, so long as we qualify as an emerging growth company, we may elect not to provide certain information, including certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and securities analysts to evaluate our company. As a result, investor confidence in our company and the market price of our common stock may be materially and adversely affected. 20 Item 3. Quantitative and Qualitative Disclosures about Market Risk Not applicable. Item 4. Controls and Procedures. Evaluation of disclosure controls and procedures Our Chief Executive Officer (who is our principal executive officer) and Chief Financial Officer (who is our principal financial officer), conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”) as of March 31, 2022. As of March 31, 2022, based upon the evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective. Disclosure controls and procedures designed to reasonably ensure that information required to be disclosed in our reports filed under the Exchange Act, such as this report, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Changes in Internal Control Over Financial Reporting There was no change in our internal control over financial reporting that occurred during the three months ended March 31, 2022 that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations on Effectiveness of Controls Our disclosure controls and procedures and internal control over financial reporting are designed to reasonably ensure that designed control objectives are achieved. Our management recognizes that any control system, no matter how well designed and operated, is based upon certain judgments and assumptions and cannot provide absolute assurance that its objectives will be met. Similarly, an evaluation of controls cannot provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. 21 PART II - OTHER INFORMATION Item 1. Legal Proceedings None Item 1A. Risk Factors There have been no material changes to the risk factors set forth in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 23, 2022 ( our “Annual Report”). Our business involves significant risks. You should carefully consider the risks and uncertainties described in our Annual Report, together with all of the other information in this Quarterly Report on Form 10-Q, as well as our audited consolidated financial statements and related notes as included in our Annual Report. The risks and uncertainties described in our Annual Report are not the only ones we face. Additional risk and uncertainties that we are unaware of or that we deem immaterial may also become important factors that adversely affect our business. The realization of any of these risks and uncertainties could have a material adverse effect on our reputation, business, financial condition, results of operations, growth and future prospects as well as our ability to accomplish our strategic objectives. In that event, the market price of our common stock could decline and you could lose part or all of your investment. Item 2. Unregistered Securities Sales of Equity Securities and Use of Proceeds Sales of Unregistered Securities There have been no sales of unregistered securities within the period covered by this report that would be required to be disclosed pursuant to Item 701 of Regulation S-K. Repurchases of Shares or of Company Equity Securities None Item 3. Default Upon Senior Securities None 22 Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information None Item 6. Exhibits The following documents are filed as a part of this report or incorporated herein by reference: Exhibit Number Description 31.1 Certification of the Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of the Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certifications of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2 Certifications of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). 23 SIGNATURES Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SEQLL INC. Date: May 12, 2022 /s/ Daniel Jones Daniel Jones Chief Executive Officer (Principal Executive Officer) Date: May 12, 2022 /s/ John W. Kennedy John W. Kennedy Chief Financial Officer (Principal Financial and Accounting Officer) 24